The global carrier screening market was valued at USD 2.05 billion in 2025. The market is projected to grow from USD 2.27 billion in 2026 to USD 5.24 billion by 2034, exhibiting a compound annual growth rate of 11.02% during the forecast period. Contrive Datum Insights presents this information in its report titled "Carrier Screening Market Size, Share & Industry Analysis, By Type (Expanded Carrier Screening, Targeted Disease Carrier Screening), Medical condition (Cystic Fibrosis, Tay-Sachs, Gaucher Disease, Sickle Cell Disease, Spinal Muscular Atrophy, Other), Technology (DNA Sequencing, Polymerase Chain Reaction, Microarrays, Other), End-user (Hospitals, Laboratories, Physician Offices & Clinics, Other), Testing mode (Physician-Ordered/Clinical Testing, Direct-to-Consumer (DTC) Testing), and Regional Forecast, 2026-2034".
Carrier screening is a genetic test that identifies whether a prospective or expecting parent carries a gene variant for an inherited condition that could be passed to a child, most often performed on a blood or saliva sample before or during pregnancy. Panels range from targeted tests built around a single condition or ethnic background to expanded panels that screen for dozens of conditions at once regardless of ancestry. Buyers include obstetric and reproductive medicine clinics, fertility centers, and the reference and specialty laboratories that process the samples and report results back to ordering physicians.
Rising adoption of expanded carrier screening panels in routine prenatal care
Rising adoption of expanded carrier screening panels in routine prenatal care is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 11.02% a year, the type lines exposed to it move fastest: Expanded Carrier Screening compounds at 13.7%, taking its share of revenue from 58.05% to 71.95% and its value from USD 1.19 billion to USD 3.77 billion.
The study also runs a bull case: assumes payer coverage for expanded carrier screening broadens faster than guidelines alone would predict, with more national and private insurers adding full panel reimbursement and pulling forward orders from patients who would otherwise pay out of pocket. That path ends 2034 at USD 6.03 billion, above the USD 5.24 billion base case.
The downside is specific. Assumes reimbursement expansion stalls in several markets and out-of-pocket cost keeps a larger share of eligible patients from testing, slowing the shift from targeted to expanded panels and holding direct-to-consumer volume below current trend, and 2034 revenue lands at USD 4.61 billion. Targeted Disease Carrier Screening is the drag, 41.95% of the 2025 base compounding at 6.03% while the market runs at 11.02%.
One Type Line Holds Both Positions
The type axis divides the field, and one line dominates both halves of it. Expanded Carrier Screening is the largest at 58.05% of 2025 revenue, worth USD 1.19 billion, and also the fastest at 13.7%, ending 2034 at 71.95%. Incumbency and momentum are not split between rivals here, leaving the position hard to attack.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Medical condition | Cystic Fibrosis | 23.9% · USD 0.49 billion | Spinal Muscular Atrophy 13.28% |
| Technology | DNA Sequencing | 55.12% · USD 1.13 billion | — |
| End-user | Laboratories | 44.88% · USD 0.92 billion | Physician Offices & Clinics 11.59% |
| Testing mode | Physician-Ordered/Clinical Testing | 87.8% · USD 1.8 billion | Direct-to-Consumer (DTC) Testing 15.85% |
- North America was the largest region in 2025, holding 41.95% of global revenue at USD 0.86 billion and reaching USD 1.94 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 19.51% in 2025 to 25.95% in 2034, with revenue growing from USD 0.4 billion to USD 1.36 billion.
- Middle East and Africa stays the smallest contributor across the period: 5.85% of revenue in 2025 and 5.92% in 2034.
- Expanded Carrier Screening was the leading type line in 2025, taking 58.05% of revenue at USD 1.19 billion.
- Expanded Carrier Screening is projected to grow at 13.7% over the forecast period, the fastest of any type line.
- The United States is the largest single country market at USD 0.73 billion in 2025, 35.61% of global revenue.
Every year from 2020 to 2034 is reported, with revenue and growth for each line across five axes: by type, and by medical condition, technology, end-user and testing mode. The headline total carries bear, base and bull cases at USD 4.61 billion and USD 6.03 billion by 2034. The study also breaks out all five regions to country level, sets out the competitive landscape, and documents the method behind every estimate. Available as a PDF, with a free sample on request.